Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
SES AI Fourth Quarter and Full Year 2025 Earnings Call - Pivot from OEM services to ESS, drones and Molecular Universe monetization
SES AI closed 2025 with a tenfold revenue increase to $21 million, but the headline is strategic pivoting more than tidy profitability. One-time OEM service work with Honda and Hyundai drove much of l...
- Revenue jumped to $21.0 million in full-year 2025 from just over $2 million in 2024, driven largely by completed OEM services and four months of UZ Energy contribution.
- Q4 2025 revenue was $4.6 million, up 124% year-over-year, but logistics delays pushed about $1.5 million of revenue into Q1 2026.
- One-time service revenue from Honda and Hyundai totaled $13.6 million in 2025 and is not expected to recur in 2026.
- +13 more takeaways
Cracker Barrel Fiscal 2026 Q2 Earnings Call - Guest experience improving, but traffic still down and EBITDA pressured
Cracker Barrel reported Q2 fiscal 2026 revenue of $874.8 million, with adjusted EBITDA of $38.2 million, down sharply from $74.6 million a year ago. Management pointed to clear operational progress — ...
- Q2 total revenue was $874.8 million, down 7.9% year over year, driven by both restaurant and retail declines.
- Adjusted EBITDA for the quarter was $38.2 million, or 4.4% of revenue, versus $74.6 million, or 7.9%, in the prior year.
- Comparable restaurant sales fell 7.1% and restaurant traffic declined 10.1% in the quarter, with November and December down roughly 10% to 11% and January improving to a 9% decline.
- +12 more takeaways
Cross Country Healthcare Q4 2025 Earnings Call - Targets >$1B Run Rate and 4%-5% Adjusted EBITDA by Year-End 2026
Cross Country Healthcare closed a bruising 2025, with Q4 revenue of $237 million (-24% YoY) and a full-year $1.05 billion (-22% YoY), but management says the worst of the disruption is behind it. With...
- Q4 2025 revenue was $237 million, down 5% sequentially and 24% year over year; full-year 2025 revenue was $1.05 billion, down 22% YoY.
- Gross profit in Q4 was $48 million, gross margin 20.3%, broadly stable across 2025 (20.0%–20.4%).
- Adjusted EBITDA was $40 million in Q4 and $27 million for the full year; full-year Adjusted EBITDA margin was about 2.5%.
- +17 more takeaways
Everspin Technologies Q4 2025 Earnings Call - MRAM Production Ramps, NOR Flash Replacement Talks Accelerate
Everspin closed Q4 with steady top-line execution, stronger product sales, and a clear product roadmap that shifts the company from niche supplier toward mainstream embedded non-volatile memory. The q...
- Q4 revenue of $14.8 million, up 12% year-over-year, and non-GAAP EPS of $0.11 per share, near the top of guidance.
- MRAM product sales were $13.5 million in Q4, up 22% year-over-year, showing product-led growth versus one-off licensing.
- Everspin recognized $2.0 million of other income in Q4, and has recorded $10.5 million to date under a $14.6 million DoD sustainment contract for onshore MRAM manufacturing, with estimated completion in H1 2027.
- +13 more takeaways
Stem Inc. Q4 2025 Earnings Call - Software-first turnaround delivers first full-year positive adjusted EBITDA and primes PowerTrack EMS for 2027 scale
Stem closed 2025 as a materially different company. Management pushed the business into a software and services focus, grew core software, services and Edge hardware revenue 25% to $141 million, and d...
- Stem declared 2025 a strategic turnaround year, shifting decisively toward a software-centric model and away from battery hardware resale.
- Full year 2025 revenue was $156 million, up 8% year-over-year, with software, services and Edge hardware at $141 million, up 25% year-over-year.
- PowerTrack-related ARR finished 2025 at $61 million, up 16% year-over-year and up 1% sequentially.
- +12 more takeaways
Cardlytics Q4 FY2025 Earnings Call - Reset to self-sustainability despite Bank of America exit and near-term supply headwinds
Cardlytics spent 2025 resetting the company: trimming costs, modernizing the tech stack, and positioning the business to be self-sustaining in 2026. The company closed out the year with positive adjus...
- Cardlytics completed a strategic reset in 2025 focused on cost discipline, product simplification, and balance sheet repair to reach self-sustainability in 2026.
- Fiscal 2025 billings were $385.0 million, down 13.3% year-over-year; revenue was $233.0 million, down 16.2% year-over-year.
- Annual Adjusted EBITDA was positive $10.1 million, up $7.5 million year-over-year, marking the third consecutive year of positive adjusted EBITDA.
- +17 more takeaways
AEO Inc. Fourth Quarter 2025 Earnings Call - Aerie and OFFLINE Power a Strong Finish Despite $130M of Tariff Headwinds
AEO closed 2025 with a decisive second-half rebound, led by Aerie and OFFLINE which together delivered outsized comps and margin leverage, offsetting heavy tariff pressure. Q4 revenue hit a record $1....
- Q4 revenue was a record $1.8 billion, up 10% year over year, with consolidated comps +8%.
- Aerie and OFFLINE drove the quarter, with Aerie/OFFLINE comps up 23% and OFFLINE described as one of the fastest growing brands in company history.
- Adjusted operating income in Q4 was $180 million, up 27% from $142 million a year ago, adjusted operating margin rose to 10.2% from 8.9%.
- +13 more takeaways
Verastem Oncology Q4 2025 Earnings Call - Commercial launch gains traction with $30.9M revenue since approval, VS-7375 advanced toward registration-directed trials
Verastem closed 2025 as a newly commercial company after FDA approval of the avutometinib plus defactinib CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer. Since approval in May, May...
- Verastem became a commercial-stage company in 2025 following FDA approval of avutometinib plus defactinib CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, with approval delivered nearly two months ahead of the PDUFA date.
- Net product revenue for the launch period May through December 2025 was $30.9 million, including $17.5 million in Q4 2025, signaling early commercial traction.
- Nearly 300 prescribers had written scripts through February 2026, prescriptions split roughly 60/40 GynOnc to MedOnc, and more than half of prescriptions originate in academic centers.
- +12 more takeaways
MicroVision Q4 2025 Earnings Call - Acquisitions accelerate Lidar 2.0 shift, guiding $10M-$15M revenue and $65M-$70M cash burn in 2026
MicroVision used the Q4 and full-year 2025 call to reposition itself as a consolidated lidar vendor for automotive, industrial, and security and defense, leaning on recent Luminar and Scantinel acquis...
- Strategic pivot to 'Lidar 2.0': MicroVision says industry is moving from hardware-spec races to value-driven, software-enabled, design-to-cost solutions focused on scalable deployments across multiple end markets.
- Material acquisitions: Luminar and Scantinel were highlighted as transformational, adding Iris and Halo long-range products, a 1550 nm FMCW capability, and about 30 new Luminar customer relationships.
- Product portfolio breadth: MicroVision now claims a full-stack portfolio spanning MOVIA short-range sensors (MOVIA L and MOVIA S), Iris and Halo long-range sensors, 1550 nm FMCW from Scantinel, plus MOSAIK and Sentinel software for perception and point-cloud processing.
- +13 more takeaways
Alto Ingredients Q4 2025 Earnings Call - Strategic realignment lifts margins, CO2 and 45Z tailwinds
Alto delivered a clear rebound in 2025, turning a multi-year loss into positive earnings by tightening costs, optimizing assets, and leaning into CO2 and premium export markets. Q4 net income swung to...
- Q4 2025 net income attributable to common stockholders was $21.5 million, about $0.28 per diluted share, a roughly $63.5 million improvement versus Q4 2024.
- Adjusted EBITDA for Q4 was $27.9 million, and for full-year 2025 was $44.7 million, up approximately $35.6 million and $53.2 million year over year respectively.
- Primary drivers of improvement were stronger crush margins (+$0.15 per gallon year over year, contributing about $8 million), higher renewable fuel export sales (about $5 million), sale of Oregon carbon credits ($2.9 million), and staffing reductions (about $2.6 million).
- +12 more takeaways